Stage I and II Follicular Non-Hodgkin’s Lymphoma: Long-Term Follow-Up of No Initial Therapy

Abstract

In selected stage I and II follicular NHL patients, deferred therapy is an acceptable approach, as more than half of our patients remained untreated at a median of 6 or more years, and survival was comparable to that seen in reports with immediate treatment.

Follicular lymphoma of the ocular adnexal region: A nation‐based study

“…Thus, observation for the present patient group is not recommended. However, observation might be a possible approach in some cases of early stage follicular lymphoma involving other sites, if radiotherapy-related complications cause significant comorbidity (Advani et al 2004). …”

Biological characterization of stage I follicular lymphoma according to extranodal or nodal primary origin and t(14;18) status using high‐resolution array‐based comparative genomic hybridization

“…FL is generally characterized by the presence of the (14;18) chromosomal translocation but prior reports indicate that 15-20% of FL lack this translocation [1]. Earlier studies using traditional cytogenetic and FISH analysis found that t(14;18) negative FL had higher frequency of Grade 3 and BCL6 translocations but these studies looked at all stages of FL.…”

“…Although generally characterized by an indolent clinical behavior, many cases eventually transform to an aggressive large B-cell lymphoma [1]. Although most of the patients have advanced disease at presentation, approximately 10-20% of patients with FL present in limited stages (Stage I-II) [1].…”

“…Although generally characterized by an indolent clinical behavior, many cases eventually transform to an aggressive large B-cell lymphoma [1]. Although most of the patients have advanced disease at presentation, approximately 10-20% of patients with FL present in limited stages (Stage I-II) [1]. In a retrospective analysis, more than half of patients with early stage FL remained untreated at a median of 6 or more years, and survival was comparable to that observed in patients undergoing immediate treatment [1].…”

“…Although most of the patients have advanced disease at presentation, approximately 10-20% of patients with FL present in limited stages (Stage I-II) [1]. In a retrospective analysis, more than half of patients with early stage FL remained untreated at a median of 6 or more years, and survival was comparable to that observed in patients undergoing immediate treatment [1]. FLs are generally characterized by the presence of the t(14;18)(q32;q21), which causes a fusion of the BCL2 oncogene with the immunoglobulin heavy chain joining region.…”